Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2024-04-24 Regulatory Filings
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Resignation of Independent director
Regulatory Filings
2024-04-24 English
Resignation
Board/Management Information Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the resignation of a director, Ms. Gita Nayyar, from Glenmark Life Sciences Limited. It references compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including changes in board composition. The content includes details about the resignation, effective date, and committee memberships affected. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of a change in the company's board of directors, fitting the category of Board/Management Information (MANG). The document length is about 4820 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is MANG with high confidence.
2024-04-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) announcing the schedule and details of an upcoming earnings call for Glenmark Life Sciences Limited. It specifies the date and time of the call, dial-in numbers, and contact persons for clarification. There is no actual financial data or analysis presented in the document, only an invitation and logistical information for the earnings call. The document length is short (2497 characters), and it serves as a notification rather than a report or transcript. According to the classification rules, such a document announcing an earnings call is best classified as a Call Transcript (CT) if it contained the transcript, but since this is only an invitation to the call, it is more appropriate to classify it as a Regulatory Filing (RNS) because it is a general regulatory announcement about the earnings call event, not the transcript or the earnings release itself.
2024-04-19 English
Board Meeting — GLENMARK LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 25-Apr-2024 to inter-alia consider and approve the Audited Financial results of the Company…
Regulatory Filings
2024-04-18 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice dated April 18, 2024, addressed to stock exchanges regarding an upcoming Board Meeting scheduled for April 25, 2024. The purpose of the meeting is to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2024. It also mentions the closure of the trading window for insiders as per SEBI regulations. The document does not contain any financial data or the actual financial results but is an announcement about the meeting where such results will be approved. The length is only 2201 characters, which is short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement informing the stock exchanges and public about the board meeting and trading window closure, not the financial report itself.
2024-04-18 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice dated April 18, 2024, addressed to stock exchanges regarding an upcoming Board Meeting scheduled for April 25, 2024. The purpose of the meeting is to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2024. It also mentions the closure of the trading window for insiders as per SEBI regulations. The document does not contain any financial data or the actual financial results but is an announcement about the meeting where such results will be approved. The document length is only 2201 characters, which is short and consistent with an announcement rather than a full report. Therefore, according to the MENU VS MEAL rule, this is an announcement of a meeting and not the financial report itself. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a board meeting and trading window closure, not a full financial report or other specific filing type.
2024-04-18 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.